

Ji-Young Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9138268/publications.pdf>

Version: 2024-02-01

62
papers

1,491
citations

270111

25
h-index

355658

38
g-index

64
all docs

64
docs citations

64
times ranked

1973
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran. <i>Pharmaceutics</i> , 2022, 14, 257.	2.0	2
2	Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans. <i>Pharmaceutics</i> , 2022, 14, 591.	2.0	0
3	Effect of Short-Term Sunlight Exposure on Blood Pressure and Pulse Rate in Vitamin D₃-Insufficient, Prehypertensive Patients: A Pilot Study. <i>Complementary Medicine Research</i> , 2021, 28, 206-215.	0.5	1
4	Effect of Memantine on QT/QTc Interval in a Healthy Korean Population. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1209-1215.	0.8	4
5	ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans. <i>Frontiers in Pharmacology</i> , 2021, 12, 658039.	1.6	0
6	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cholic Acid (MT921) after a Subcutaneous Injection in the Submental Area to Humans. <i>Pharmaceutics</i> , 2021, 14, 830.	1.7	1
7	Effects of age and gender on the cytochrome P450 2D6 activity in a Korean population. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1659-1664.	0.7	1
8	Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Tenofovir in Humans. <i>Frontiers in Pharmacology</i> , 2021, 12, 736317.	1.6	1
9	Development and validation of LC-MS/MS method for simultaneous determination of dabigatran etexilate and its active metabolites in human plasma, and its application in a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114220.	1.4	5
10	Rapid detection of FMO3 single nucleotide polymorphisms using a pyrosequencing method. <i>Molecular Medicine Reports</i> , 2021, 25, .	1.1	2
11	Development of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4721.	0.8	4
12	Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K ₁ . <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1453-1461.	1.0	7
13	Pharmacokinetic Analysis and Biomarker-Assisted Safety Assessment of Acetaminophen in Combination With Ojeoksan Compared With Acetaminophen Alone. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1485-1494.	1.0	1
14	Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 125, 345-352.	1.2	10
15	Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 720-725.	0.7	3
16	Clinical utility of a novel natural killer cell activity assay for diagnosing non-small cell lung cancer: a prospective pilot study. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1661-1669.	1.0	14
17	Effects of Ojeoksan on the Pharmacokinetics of Celecoxib at Steady-State in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 51-57.	1.2	13
18	Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1281-1289.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Vesicular monoamine transporter 1 gene polymorphism and white matter integrity in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 138-145.	2.5	13
20	Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy. <i>Cancer Research and Treatment</i> , 2015, 47, 509-517.	1.3	35
21	Pharmacokinetics and Safety Profile of DA-3803, a Proposed Biosimilar of Recombinant Human Chorionic Gonadotropin, in Healthy Subjects. <i>BioDrugs</i> , 2015, 29, 199-205.	2.2	2
22	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. <i>Clinica Chimica Acta</i> , 2015, 438, 7-11.	0.5	7
23	<i>CYP3A5</i> Polymorphism and Its Clinical Implications and Pharmacokinetic Role. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 3.	0.3	6
24	Multiplex pyrosequencing method to determine <i>CYP2C9</i> , <i>VKORC1</i> , and <i>CYP4F2</i> polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups. <i>Molecular Biology Reports</i> , 2014, 41, 7305-7312.	1.0	12
25	<i>SLCO2B1</i> genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations. <i>Molecular Biology Reports</i> , 2013, 40, 4211-4217.	1.0	8
26	Single-Dose, Randomized Crossover Comparisons of Different-Strength Imatinib Mesylate Formulations in Healthy Korean Male Subjects. <i>Clinical Therapeutics</i> , 2013, 35, 1595-1602.	1.1	4
27	Effect of <i>P2Y1</i> and <i>P2Y12</i> genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. <i>Thrombosis Research</i> , 2013, 132, 221-226.	0.8	20
28	Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 913-919.	1.1	5
29	Effects of polymorphisms of the <i>SLCO2B1</i> transporter gene on the pharmacokinetics of montelukast in humans. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1186-1193.	1.0	27
30	Pharmacokinetic Comparison of Orally Disintegrating and Conventional Donepezil Formulations in Healthy Korean Male Subjects: A Single-Dose, Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study. <i>Clinical Therapeutics</i> , 2011, 33, 965-972.	1.1	9
31	Effect of <i>ABCG2</i> genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 129-134.	0.8	43
32	Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 721-725.	0.8	14
33	Effect of <i>cytochrome P450 3A5</i> genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects. <i>Chirality</i> , 2009, 21, 485-491.	1.3	10
34	Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 609-614.	0.8	74
35	Effects of <i>CYP2D6</i> and <i>CYP3A5</i> Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 272-277.	0.7	42
36	Effect of <i>CYP3A5</i> genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 589-597.	0.8	41

#	ARTICLE	IF	CITATIONS
37	Effect of Rifampin, an Inducer of CYP3A and P-glycoprotein, on the Pharmacokinetics of Risperidone. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 66-72.	1.0	39
38	Effect of Polymorphic CYP3A5 Genotype on the Single-Dose Simvastatin Pharmacokinetics in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 87-93.	1.0	90
39	Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 53-58.	1.1	42
40	Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 339-345.	1.1	21
41	Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: A randomized, open-label, two-period, comparative, crossover study. <i>Clinical Therapeutics</i> , 2006, 28, 1837-1847.	1.1	38
42	Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 135-142.	0.7	33
43	Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 109-114.	1.0	9
44	Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 590-599.	2.3	52
45	Effect of CYP3A53 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 646-656.	2.3	53
46	Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 520-528.	2.3	52
47	Effect of Quercetin on the Pharmacokinetics of Rosiglitazone, a CYP2C8 Substrate, in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 941-946.	1.0	26
48	Inhibitory effect of Loperamide on Cytochrome P450 3A4 in Human Liver Microsomes. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2005, 13, 84.	0.1	0
49	Effect of Licorice (<i>Radix Glycyrrhizae</i>) Water Extract on the Pharmacokinetics and the Pharmacodynamics of Midazolam in Healthy Subjects. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2005, 13, 45.	0.1	0
50	Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 397-402.	1.1	42
51	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 575-581.	0.8	71
52	Simple and extractionless high-performance liquid chromatographic determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. <i>Biomedical Chromatography</i> , 2004, 18, 613-615.	0.8	33
53	Quantification of gliclazide by semi-micro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 35, 943-949.	1.4	28
54	Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 157-162.	2.3	82

#	ARTICLE	IF	CITATIONS
55	Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: A randomized, open-label, two-period, comparative crossover study. <i>Clinical Therapeutics</i> , 2004, 26, 2092-2101.	1.1	17
56	Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. <i>Clinical Therapeutics</i> , 2004, 26, 715-723.	1.1	44
57	Inhibitory Effects of Macrolide Antibiotics on Cytochrome P450 3A4 by Human Liver Microsomes. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 2004, 12, 129.	0.1	0
58	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. <i>Archives of Pharmacal Research</i> , 2003, 26, 631-637.	2.7	121
59	Inhibitory effect of 5-fluorouracil on human cytochrome P 450 isoforms in human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 407-409.	0.8	24
60	Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 334-340.	2.3	62
61	Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3464-3469.	1.4	40
62	INHIBITORY EFFECT OF GLYBURIDE ON HUMAN CYTOCHROME P450 ISOFORMS IN HUMAN LIVER MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1090-1092.	1.7	26